An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID:
MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAPK3 protein]] which results in increased susceptibility to Doxorubicin; [Doxorubicin co-treated with Carvedilol] results in increased phosphorylation of MAPK3 protein; [Doxorubicin co-treated with Razoxane] results in increased phosphorylation of MAPK3 protein; Acetylcysteine inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; diallyl trisulfide inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; Doxorubicin results in increased activity of and results in increased localization of MAPK3 protein; Doxorubicin results in increased activity of and results in increased phosphorylation of MAPK3 protein; Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein; galangin inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; kaempferol inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; pifithrin inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Doxorubicin results in increased localization of MAPK3 protein modified form]; U 0126 inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased phosphorylation of MAPK3 protein; [Doxorubicin co-treated with dimethyl sulfone] results in increased phosphorylation of MAPK3 protein; [Quercetin co-treated with Doxorubicin] results in increased phosphorylation of MAPK3 protein; Acetaminophen inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Doxorubicin affects the phosphorylation of and affects the activity of MAPK3 protein; Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of MAPK3 protein]; lercanidipine inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; SOD2 protein affects the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]
CSF3 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; Doxorubicin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; EPO protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; Genistein inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; HGF protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]; HGF protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MAPK3 protein]; NRG1 protein affects the reaction [Doxorubicin affects the phosphorylation of MAPK3 protein]; pifithrin promotes the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]
